6.
van den Hoek A, de Jong J, Worms N, van Nieuwkoop A, Voskuilen M, Menke A
. Diet and exercise reduce pre-existing NASH and fibrosis and have additional beneficial effects on the vasculature, adipose tissue and skeletal muscle via organ-crosstalk. Metabolism. 2021; 124:154873.
DOI: 10.1016/j.metabol.2021.154873.
View
7.
Nakagawa H
. Recent advances in mouse models of obesity- and nonalcoholic steatohepatitis-associated hepatocarcinogenesis. World J Hepatol. 2015; 7(17):2110-8.
PMC: 4539404.
DOI: 10.4254/wjh.v7.i17.2110.
View
8.
Wang Y, Leaker B, Qiao G, Sojoodi M, Eissa I, Epstein E
. Precision-cut liver slices as an ex vivo model to evaluate antifibrotic therapies for liver fibrosis and cirrhosis. Hepatol Commun. 2024; 8(11).
PMC: 11512631.
DOI: 10.1097/HC9.0000000000000558.
View
9.
Lambrecht J, Verhulst S, Reynaert H, van Grunsven L
. The miRFIB-Score: A Serological miRNA-Based Scoring Algorithm for the Diagnosis of Significant Liver Fibrosis. Cells. 2019; 8(9).
PMC: 6770498.
DOI: 10.3390/cells8091003.
View
10.
Ip E, Farrell G, Hall P, Robertson G, Leclercq I
. Administration of the potent PPARalpha agonist, Wy-14,643, reverses nutritional fibrosis and steatohepatitis in mice. Hepatology. 2004; 39(5):1286-96.
DOI: 10.1002/hep.20170.
View
11.
Savard C, Tartaglione E, Kuver R, Haigh W, Farrell G, Subramanian S
. Synergistic interaction of dietary cholesterol and dietary fat in inducing experimental steatohepatitis. Hepatology. 2012; 57(1):81-92.
PMC: 5341743.
DOI: 10.1002/hep.25789.
View
12.
Yin M, Woollard J, Wang X, Torres V, Harris P, Ward C
. Quantitative assessment of hepatic fibrosis in an animal model with magnetic resonance elastography. Magn Reson Med. 2007; 58(2):346-53.
DOI: 10.1002/mrm.21286.
View
13.
Shao W, Ichimura-Shimizu M, Ogawa H, Jin S, Sutoh M, Nakamura S
. Establishment of repeated liver biopsy technique in experimental mice. Heliyon. 2023; 9(6):e16978.
PMC: 10361027.
DOI: 10.1016/j.heliyon.2023.e16978.
View
14.
Yehezkel A, Abudi N, Nevo Y, Benyamini H, Elgavish S, Weinstock M
. AN1284 attenuates steatosis, lipogenesis, and fibrosis in mice with pre-existing non-alcoholic steatohepatitis and directly affects aryl hydrocarbon receptor in a hepatic cell line. Front Endocrinol (Lausanne). 2023; 14:1226808.
PMC: 10469006.
DOI: 10.3389/fendo.2023.1226808.
View
15.
Mollerhoj M, Veidal S, Thrane K, Oro D, Overgaard A, Salinas C
. Hepatoprotective effects of semaglutide, lanifibranor and dietary intervention in the GAN diet-induced obese and biopsy-confirmed mouse model of NASH. Clin Transl Sci. 2022; 15(5):1167-1186.
PMC: 9099137.
DOI: 10.1111/cts.13235.
View
16.
Yong H, Shan S, Wang S, Liu Z, Liu Z, Zhang C
. Activation of mitophagy by rapamycin eliminated the accumulation of TDP-43 on mitochondrial and promoted the resolution of carbon tetrachloride-induced liver fibrosis in mice. Toxicology. 2022; 471:153176.
DOI: 10.1016/j.tox.2022.153176.
View
17.
Ellis E, Mann D
. Clinical evidence for the regression of liver fibrosis. J Hepatol. 2012; 56(5):1171-1180.
DOI: 10.1016/j.jhep.2011.09.024.
View
18.
Lee M
. A review of liver fibrosis and cirrhosis regression. J Pathol Transl Med. 2023; 57(4):189-195.
PMC: 10369136.
DOI: 10.4132/jptm.2023.05.24.
View
19.
Olinga P, Schuppan D
. Precision-cut liver slices: a tool to model the liver ex vivo. J Hepatol. 2013; 58(6):1252-3.
DOI: 10.1016/j.jhep.2013.01.009.
View
20.
Febbraio M, Reibe S, Shalapour S, Ooi G, Watt M, Karin M
. Preclinical Models for Studying NASH-Driven HCC: How Useful Are They?. Cell Metab. 2018; 29(1):18-26.
PMC: 6326872.
DOI: 10.1016/j.cmet.2018.10.012.
View